Anti-Nogo-A antibody: a treatment option for neurogenic lower urinary tract dysfunction?

BJU Int. 2015 Apr:115 Suppl 6:16-7. doi: 10.1111/bju.13007.

Authors

Marc P Schneider¹, Martin E Schwab, Thomas M Kessler

Affiliation

¹ Brain Research Institute, University of Zürich, Zürich, Switzerland; Neuro-Urology, Spinal Cord Injury Center and Research, Balgrist University Hospital, University of Zürich, Zürich, Switzerland; Department of Health Sciences and Technology, ETH Zürich, Zürich, Switzerland.

PMID: 25430943
DOI: 10.1111/bju.13007

No abstract available

MeSH terms

Animals
Antibodies / therapeutic use*
Clinical Trials as Topic
GPI-Linked Proteins / antagonists & inhibitors
Humans
Lower Urinary Tract Symptoms / etiology
Lower Urinary Tract Symptoms / therapy*
Myelin Proteins / antagonists & inhibitors
Myelin Proteins / immunology*
Nerve Regeneration / physiology*
Nogo Proteins
Nogo Receptor 1
Rats
Receptors, Cell Surface / antagonists & inhibitors
Spinal Cord Injuries / complications
Urinary Bladder, Neurogenic / etiology
Urinary Bladder, Neurogenic / therapy*

Substances

Antibodies
GPI-Linked Proteins
Myelin Proteins
Nogo Proteins
Nogo Receptor 1
RTN4 protein, human
RTN4R protein, human
Receptors, Cell Surface
Rtn4 protein, rat